[Federal Register Volume 65, Number 99 (Monday, May 22, 2000)]
[Notices]
[Page 32114]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-12747]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on June 15, 2000, from 8 
a.m. to 5 p.m. and on June 16, 2000, from 9 a.m. to 12:30 p.m.
    Location: Holiday Inn, 8777 Georgia Ave., Silver Spring, MD.
    Contact Person: Linda A. Smallwood, Center for Biologics Evaluation 
and Research (HFM-302), Food and Drug Administration, 1401 Rockville 
Pike, Rockville, MD 20852-1448, 301-827-3514, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 19516. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: On June 15, 2000, the committee will hear updates on 
summaries of the Public Health Service Advisory Committee on Blood 
Safety and Availability meeting, April 25 and 26, 2000; FDA's 
Transmissible Spongiform Encephalopathies Advisory Committee meeting, 
June 1 and 2, 2000; the FDA-sponsored workshop on plasticizers, October 
18, 1999; and a briefing on blood supply monitoring. The committee will 
also hear presentations and provide recommendations on plasma pool 
screening by nucleic acid tests for Hepatitis A virus and, in the 
afternoon, the committee will hear presentations and provide 
recommendations on the development of rapid human immunodeficiency 
virus (HIV) tests. On June 16, 2000, the committee will hear updates on 
the requirements for syphilis testing, the risk of Hepatitis C virus to 
sexual partners, and relative sensitivity of Hepatitis B surface 
antigen and Hepatitis B virus nucleic acid tests. Also, the committee 
will hear and discuss presentations on the proposed document entitled 
``FDA Guidance on Universal Leukoreduction: Current Thinking.''
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by Friday, June 
2, 2000. Oral presentations from the public will be scheduled between 
approximately 11 a.m. to 11:30 a.m. and 2:30 p.m. to 3:30 p.m. on June 
15, 2000, and between approximately 10:30 a.m. to 11:30 a.m. on June 
16, 2000. Time allotted for each presentation may be limited. Those 
desiring to make formal oral presentations should notify the contact 
person before Friday, June 9, 2000, and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names and addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: May 11, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-12747 Filed 5-19-00; 8:45 am]
BILLING CODE 4160-01-F